Market revenue in 2023 | USD 446.6 million |
Market revenue in 2030 | USD 1,004.0 million |
Growth rate | 12.3% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.96% in 2023. Horizon Databook has segmented the Germany immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
Germany is witnessing significant demand for immunoassay-based diagnostics products to diagnose various neurological diseases such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. This growth can be attributed to the presence of leading manufacturers, such as QIAGEN, which continuously invest in the country’s market.
For instance, in April 2022, QIAGEN Digital Insights launched the QIAGEN Biomedical Knowledge Base in Europe, North America, Australia, and Japan to strengthen data science applications in biotechnology and pharmaceuticals.
This launch provides researchers with a powerful tool to fast-track research on disease subtypes, disease mechanisms, biomarkers, and target identification. In addition, in September 2022, QIAGEN partnered with Neuron23 to develop an assay that can detect biomarkers discovered by Neuron23 and predict the responsiveness of Parkinson’s disease to the LRRK2 inhibitor.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Germany immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account